A Rare Case of Systemic AL Amyloidosis with Muscle Involvement: A Misleading Diagnosis
暂无分享,去创建一个
C. Mancini | F. Aversa | V. Pietrini | G. Cenacchi | N. Giuliani | V. Papa | L. Verga | E. Martella | F. Accardi | B. Dalla Palma | R. Costa | L. Notarfranchi | A. Capozzi | G. Capello
[1] M. Milone,et al. Characterization of isolated amyloid myopathy , 2017, European journal of neurology.
[2] D. Dingli,et al. Systemic Immunoglobulin Light Chain Amyloidosis-Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. , 2016, Mayo Clinic proceedings.
[3] R. Walters,et al. Muscle diseases: mimics and chameleons , 2014, Practical Neurology.
[4] G. Merlini,et al. Systemic light chain amyloidosis: an update for treating physicians. , 2013, Blood.
[5] M. Dimopoulos,et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. , 2013, Blood.
[6] A. Mammen,et al. Expanding the spectrum of monoclonal light chain deposition disease in muscle , 2012, Muscle & nerve.
[7] U. Hellman,et al. Germ Line Origin and Somatic Mutations Determine the Target Tissues in Systemic AL-Amyloidosis , 2007, PloS one.
[8] R. Falk,et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis , 2005, American journal of hematology.
[9] M. Kornfeld,et al. Amyloid myopathy: Characteristic features of a still underdiagnosed disease , 2005, Muscle & nerve.
[10] T. Therneau,et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Giampaolo Merlini,et al. Molecular mechanisms of amyloidosis. , 2003, The New England journal of medicine.
[12] A. Engel,et al. Amyloid myopathy: An underdiagnosed entity , 1998, Annals of neurology.
[13] W. Brown,et al. Myopathy in Primary Systemic Amyloidosis , 1988, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[14] M. Fardeau,et al. In vitro myotrophic effect of serum kappa chain immunoglobulins from a patient with kappa light chain myeloma and muscular hypertrophy. , 1986, The Journal of clinical investigation.
[15] G. Merlini,et al. Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium , 2015, Advances in Therapy.